

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-46 (Cancelled)

47 (Currently amended). A method to treat a living body suffering from a disease selected from the group consisting of asthma, rejection reactions relating to grafting organs or tissues, graft-versus-host disease, rheumatoid arthritis, sepsis, autoimmune disease, and inflammatory diseases, comprising administering an effective amount of a composition to the living body, wherein said composition comprises (i) an artificially produced peptide for neutralizing a biological activity of interleukin-18, which peptide comprises variants of the amino acid sequences of the constant regions of a non-human interleukin-18 antibody, and a part or the whole of the amino acid sequences of variable regions in a naturally occurring human or non-human interleukin-18 antibody, said ~~constant regions~~ variants being not equal to the amino acid sequences of the constant regions of said non-human interleukin-18 antibody, and (ii) a pharmaceutically acceptable carrier.

48 (Currently amended). A method to treat a living body in need of immunosuppressive or anti-inflammatory treatment,

comprising administering an effective amount of a composition to the living body, wherein said composition comprises (i) an artificially produced peptide for neutralizing a biological activity of interleukin-18, which peptide comprises variants of the amino acid sequences of the constant regions of a non-human interleukin-18 antibody, and a part or the whole of the amino acid sequences of variable regions in a naturally occurring human or non-human interleukin-18 antibody, said ~~constant regions~~ variants being not equal to the amino acid sequences of the constant regions of said non-human interleukin-18 antibody, and (ii) a pharmaceutically acceptable carrier.

49(Currently amended). A method to treat a living body suffering from a disease selected from the group consisting of asthma, rejection reactions relating to grafting organs or tissues, graft-versus-host disease, rheumatoid arthritis, sepsis, autoimmune disease, and inflammatory diseases, comprising administering an effective amount of a composition to the living body, said composition comprising (i) an artificially produced peptide for neutralizing a biological activity of interleukin-18, which peptide comprises variants of the amino acid sequences of the constant regions of a non-human interleukin-18 antibody, and a part or the whole of the amino acid sequences of variable regions in a naturally occurring human or non-human interleukin-18 antibody, said ~~constant regions~~ variants being not equal to the

amino acid sequences of the constant regions of said non-human interleukin-18 antibody, and (ii) a pharmaceutically acceptable carrier, wherein the interleukin-18-neutralizing activity of said peptide per antigen-binding site is not lower than that of an immunoglobulin molecule comprising the amino acid sequences of SEQ ID NOs:1 and 2 as the light and heavy chain variable regions respectively.

50 (Currently amended). A method to treat a living body in need of immunosuppressive or anti-inflammatory treatment, comprising administering an effective amount of a composition to the living body, said composition comprising (i) an artificially produced peptide for neutralizing a biological activity of interleukin-18, which peptide comprises variants of the amino acid sequence of the constant regions of a non-human interleukin-18 antibody, and a part or the whole of the amino acid sequences of variable regions in a naturally occurring human or non-human interleukin-18 antibody, said ~~constant regions~~ variants being not equal to the amino acid sequences of the constant regions of said non-human interleukin-18 antibody, and (ii) a pharmaceutically acceptable carrier, wherein the interleukin-18-neutralizing activity of said peptide per antigen-binding site is not lower than that of an immunoglobulin molecule comprising the amino acid sequences of SEQ ID NOs:1 and 2 as the light and heavy chain variable regions respectively.

Appln. No. 09/924,099
Amd. dated August 31, 2004
Reply to Office Action of April 7, 2004

51 (Currently amended). The method of claim 47, wherein said artificially produced peptide is administered to said living ~~befy~~ body at a dose of 1 μ g to 1g per shot.

52 (Previously presented). The method of claim 48, wherein said artificially produced peptide is administered to said living body at a dose of 1 μ g to 1g per shot.

53 (Previously presented). The method of claim 49, wherein said artificially produced peptide is administered to said living body at a dose of 1 μ g to 1g per shot.

54 (Previously presented). The method of claim 50, wherein said artificially produced peptide is administered to said living body at a dose of 1 μ g to 1g per shot.